Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics150
Neuroscience & CNS90
Immunology & Autoimmune79
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms146
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $0.8t | $925.92 | +2.4% | 3.3M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.6t | $233.90 | -0.3% | 8.9M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $377.0b | $208.56 | -0.2% | 9.0M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $300.7b | $204.95 | +2.2% | 1.2M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $292.0b | $119.00 | +3.1% | 16.2M |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $188.1b | $355.24 | +1.7% | 3.7M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $178.3b | $526.29 | +2.0% | 2.0M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $169.2b | $137.64 | -0.7% | 7.3M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $158.0b | $27.61 | +1.4% | 30.1M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $122.0b | $60.29 | +2.3% | 11.5M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $112.6b | $441.20 | +1.3% | 1.0M |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $79.2b | $750.74 | +0.6% | 513.0K |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $41.9b | $309.83 | -3.2% | 1.5M |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $33.0b | $144.51 | +1.2% | 2.0M |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $31.7b | $121.73 | +2.9% | 4.0M |
 WAT | Waters Corp | Clinical-Stage Platforms | $28.8b | $327.77 | +2.7% | 439.2K |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $27.9b | $176.46 | +2.6% | 1.6M |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $27.5b | $177.33 | +0.7% | 1.2M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $25.8b | $588.10 | +1.3% | 682.5K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $19.9b | $50.00 | +3.1% | 3.0M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $19.1b | $53.73 | -1.7% | 13.6M |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $18.9b | $29.80 | +2.1% | 6.5M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $18.0b | $97.81 | +2.6% | 1.5M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $17.7b | $273.73 | +1.5% | 837.4K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.4b | $76.78 | -0.9% | 2.0M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.2b | $25.14 | +2.9% | 4.9M |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $13.1b | $520.52 | +0.9% | 626.3K |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $12.9b | $133.24 | +3.8% | 1.7M |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.0b | $75.72 | +0.6% | 1.7M |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.6b | $531.77 | +1.3% | 341.9K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.5b | $28.77 | -5.9% | 153.0K |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $11.3b | $203.41 | +2.8% | 634.8K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $10.5b | $54.65 | +1.0% | 2.1M |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $9.5b | $93.96 | +4.9% | 1.1M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $8.2b | $189.08 | +2.7% | 767.4K |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $59.25 | +3.3% | 1.9M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $8.1b | $41.24 | +0.7% | 1.7M |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $8.1b | $69.62 | +2.4% | 4.3M |
 ICLR | Icon Plc | Clinical-Stage Platforms | $8.0b | $119.59 | +3.5% | 1.2M |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.9b | $62.31 | +0.2% | 1.2M |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $7.9b | $185.84 | +5.0% | 745.3K |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $7.8b | $66.69 | +1.9% | 1.5M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $7.7b | $342.23 | +6.8% | 425.3K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.4b | $69.29 | +4.0% | 1.7M |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $7.2b | $274.26 | +3.9% | 327.2K |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $6.8b | $7.68 | +5.9% | 21.5M |
 KYMR | Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $6.5b | $87.69 | +1.8% | 587.4K |
 PTGX | Protagonist Therapeutics, Inc | Immunology & AutoimmuneMetabolic & Cardiometabolic | $6.4b | $106.05 | +2.2% | 1.0M |
 RGEN | Repligen Corp | Clinical-Stage Platforms | $6.3b | $131.17 | +3.2% | 1.1M |
 TERN | Terns Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $6.0b | $52.64 | -0.1% | 6.4M |